VEST
Research type
Research Study
Full title
VEST: The UK Vedolizumab real life experience study in inflammatory bowel disease
IRAS ID
193055
Contact name
JR Fraser Cummings
Contact email
Sponsor organisation
University Hospital Southampton NHS Trust
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
Vedolizumab has been recently licensed for use in the management of ulcerative colitis (UC) and Crohn's disease (CD) and approved by NICE. However, there is a paucity of real life outcomes data currently to inform decisions about it's optimal use in clinical settings. This clinical observation study aims to capture the experience of this new therapy across the UK. Any hospital in the UK will be eligible to participate in the study and all adult patients treated with vedolizumab will be eligible for the study. Patients will complete a number of simple questionnaires whilst they have their vedolizumab infusions during their first year of treatment. Teams will record data such as details of the patient's IBD such as accurate characterisation of their disease, medications, previous history and blood tests that are taken part of the patients routine clinical data.
REC name
London - Hampstead Research Ethics Committee
REC reference
16/LO/0127
Date of REC Opinion
21 Mar 2016
REC opinion
Further Information Favourable Opinion